Intervention

PF-08046054

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting2

Common conditions11

Lead sponsors shown2

Clinical trials

2 shown

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29

A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762 · 2022-10-25

Common conditions

Carcinoma, Non-Small-Cell Lung1 Endometrial Cancer1 Esophageal Squamous Cell Carcinoma1 Gastric Cancer1 Hepatocellular Carcinoma1 Non-small Cell Carcinoma1 Non-Small Cell Lung Cancer Metastatic1 Non-Small Cell Lung Carcinoma1 Pancreatic Adenocarcinoma1 Squamous Cell Carcinoma of the Head and Neck1 Triple Negative Breast Neoplasms1

Leading sponsors

Pfizer1 Seagen, a wholly owned subsidiary of Pfizer1

Trial status mix

RECRUITING2

Phase mix

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.